Corient Private Wealth LP Invests $2.60 Million in Collegium Pharmaceutical, Inc. $COLL

Corient Private Wealth LP acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the second quarter, HoldingsChannel reports. The institutional investor acquired 71,898 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,604,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of America Corp DE bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $9,882,000. Freestone Grove Partners LP purchased a new stake in shares of Collegium Pharmaceutical in the second quarter worth $1,611,000. Jupiter Topco LLC purchased a new stake in shares of Collegium Pharmaceutical in the second quarter worth $77,743,000. Hsbc Holdings PLC bought a new stake in shares of Collegium Pharmaceutical during the 2nd quarter valued at $1,424,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Collegium Pharmaceutical during the 2nd quarter valued at $720,000.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on COLL shares. Piper Sandler restated a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Barclays lowered their price objective on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 19th. Finally, Needham & Company LLC dropped their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Collegium Pharmaceutical Trading Up 1.3%

Collegium Pharmaceutical stock opened at $24.30 on Thursday. The stock has a market cap of $791.21 million, a P/E ratio of 19.60 and a beta of 0.72. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. Collegium Pharmaceutical, Inc. has a 1 year low of $23.84 and a 1 year high of $50.79. The firm’s 50 day moving average price is $32.34 and its 200-day moving average price is $34.53.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. During the same quarter in the previous year, the firm earned $1.68 earnings per share. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.